Mesoblast Management

Management criteria checks 3/4

Mesoblast's CEO is Silviu Itescu, appointed in Jan 2004, has a tenure of 20.83 years. total yearly compensation is $2.02M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 6.92% of the company’s shares, worth $80.29M. The average tenure of the management team and the board of directors is 5.1 years and 7.2 years respectively.

Key information

Silviu Itescu

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage	25.0%
CEO tenure	20.8yrs
CEO ownership	6.9%
Management average tenure	5.1yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Silviu Itescu's remuneration changed compared to Mesoblast's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	US$2m	US$505k	-US$88m
Mar 31 2024	n/a	n/a	-US$82m
Dec 31 2023	n/a	n/a	-US$73m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	US$1m	US$673k	-US$82m
Mar 31 2023	n/a	n/a	-US$81m
Dec 31 2022	n/a	n/a	-US$84m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	US$1m	US$697k	-US$91m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	n/a	n/a	-US$97m
Sep 30 2021	n/a	n/a	-US$97m
Jun 30 2021	US$2m	US$757k	-US$99m
Mar 31 2021	n/a	n/a	-US$109m
Dec 31 2020	n/a	n/a	-US$98m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	US$2m	US$697k	-US$78m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	n/a	n/a	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	US$1m	US$709k	-US$90m
Mar 31 2019	n/a	n/a	-US$90m
Dec 31 2018	n/a	n/a	-US$86m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	US$2m	US$748k	-US$35m

Compensation vs Market: Silviu's total compensation ($USD2.02M) is below average for companies of similar size in the US market ($USD3.22M).

Compensation vs Earnings: Silviu's compensation has increased whilst the company is unprofitable.

CEO

Silviu Itescu (67 yo)

20.8yrs

Tenure

US$2,017,166

Compensation

Dr. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Silviu Itescu	Founder	20.8yrs	US$2.02m	6.92% $ 80.3m
Eric Rose	Chief Medical Officer & Executive Director	2.8yrs	US$1.53m	0.036% $ 418.6k
Andrew Chaponnel	Interim Chief Finance Officer	3.3yrs	no data	no data
Peter Howard	General Counsel & Corporate Executive	13.3yrs	no data	no data
Paul Simmons	Scientific Advisor to the Chief Executive Officer	13.8yrs	no data	no data
Geraldine Storton	Head of Regulatory Affairs & Quality Management	no data	no data	no data
Justin Horst	Head of Manufacturing	no data	no data	no data
Fiona See	Senior VP & Head of Translational Research	no data	no data	no data
Niva Sivakumar	Joint Company Secretary	5.1yrs	no data	no data
Paul Hughes	Joint Company Secretary	2.6yrs	no data	no data
Kenneth Borow	Executive	no data	no data	no data

5.1yrs

Average Tenure

67yo

Average Age

Experienced Management: MEOB.F's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Silviu Itescu	Founder	17.4yrs	US$2.02m	6.92% $ 80.3m
Eric Rose	Chief Medical Officer & Executive Director	11.6yrs	US$1.53m	0.036% $ 418.6k
Philip Facchina	Independent Non-Executive Director	3.7yrs	US$112.47k	0.011% $ 125.3k
William A. Burns	Independent Non-Executive Vice Chairman	10.7yrs	US$134.05k	0.0093% $ 108.0k
Henry Krum	Member of Scientific Advisory Board	no data	no data	no data
Joseph Lane	Member of Scientific Advisory Board	no data	no data	no data
Robert Graham	Member of Scientific Advisory Board	no data	no data	no data
Jane Bell	Independent Non-Executive Chairman	2.3yrs	US$153.70k	0.048% $ 552.6k
Richard Gilbert	Member of Scientific Advisory Board	no data	no data	no data
Stephen Graves	Member of Scientific Advisory Board	no data	no data	no data
Philip Krause	Non-Independent Non Executive Director	2.7yrs	US$343.70k	0.025% $ 292.3k

7.2yrs

Average Tenure

70yo

Average Age

Experienced Board: MEOB.F's board of directors are considered experienced (7.2 years average tenure).

Mesoblast Management

Management criteria checks 3/4

Key information

Recent management updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Announces Board Changes

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been File Against Precigen, Royal Caribbean, Mesoblast and Loop Industries

The Law Offices of Frank R. Cruz Announces Class Action Lawsuit Against Mesoblast Limited

Rosen Law Firm Reminds Mesoblast Limited Investors of Important Deadline

Mesoblast Limited Announces Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Mesoblast Limited

Mesoblast Limited Announces US Food and Drug Administration Issues Complete Response Letter to its Biologics License Application

Mesoblast Limited Announces Updates on RYONCIL

Mesoblast Limited Receives Complete Response Letter from US Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Auditor Raises 'Going Concern' Doubt

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.33959 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age